Acquiring Company
Eli Lilly and Company
Acquired Company
Curevo LimmaTech Biologics AG and Vaccine Company
IndianapolisManufacturingBiotechnologyHealth CareMedicalPharmaceuticalBiotechnologyHealth CareDescription
Eli Lilly has spent $3.8 billion to acquire three vaccine-focused businesses: Curevo, LimmaTech Biologics AG, and Vaccine Company. This acquisition is part of Eli Lilly's strategy to expand its presence in the infectious disease field. Although it may not immediately impact financial performance, the move aims to diversify the company's portfolio. The focus remains on the successful GLP-1 drugs, but this investment in vaccines signals a long-term growth strategy.
Other recent acquisitions in Medical and Pharmaceutical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- ESTEVE acquires TerSera's Infusion Business Unit (May 4, 2026)
- Eli Lilly to acquire Ajax Therapeutics for $2.3B, $2.3B (April 27, 2026)
- DePuy Synthes acquires Expanding Innovations for growth (July 16, 2026)
- Zimmer Biomet to acquire Iovera for $140M, $140M (July 9, 2026)
- Towa Pharmaceutical acquires Tanabe's plants (July 8, 2026)
- Tarsus acquires iRenix Medical for IRX-101 development (July 8, 2026)
Who to call at Eli Lilly and Company, and when
When Eli Lilly and Company changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Eli Lilly and Company raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Eli Lilly and Company, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Eli Lilly and Company. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Eli Lilly and Company makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Curevo LimmaTech Biologics AG and Vaccine Company?
Curevo LimmaTech Biologics AG and Vaccine Company was acquired by Eli Lilly and Company, based in Indianapolis. The deal was reported on June 6, 2026. Lilly is a medicine company turning science into healing to make life better for people around the world. Eli Lilly and Company is publicly traded (LLY) and operates in Manufacturing.
When did Eli Lilly and Company acquire Curevo LimmaTech Biologics AG and Vaccine Company?
Eli Lilly and Company's acquisition of Curevo LimmaTech Biologics AG and Vaccine Company was reported on June 6, 2026. Eli Lilly has spent $3.8 billion to acquire three vaccine-focused businesses: Curevo, LimmaTech Biologics AG, and Vaccine Company. This acquisition is part of Eli Lilly's strategy to expand its presence in the infectious disease field. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Curevo LimmaTech Biologics AG and Vaccine Company do?
Curevo is known for its work in vaccine development, focusing on innovative solutions to combat infectious diseases. LimmaTech Biologics AG specializes in next-generation vaccine technologies. It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.